Novo Nordisk, European Union

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Novo Nordisk’s blockbuster drug Ozempic got another star added to its label Thursday, in an encouraging sign for the broadening of the markets for GLP-1 drugs beyond weight-loss and diabetes. Yet, strides by its U.
Novo Nordisk’s Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks
Novo Nordisk said the European Union’s drug regulator supports a label expansion of its Ozempic diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease in adults with Type 2 diabetes.
Novo Nordisk's Ozempic set to include kidney treatment label in EU
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The decision was based on findings of a trial,
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction.
Novo Nordisk's Ozempic Gets CHMP's Positive Opinion To Include Kidney Disease Label Update
The decision was based on findings of the FLOW trial, which assessed the risk reduction from Ozempic therapy, a once-weekly subcutaneous semaglutide, in chronic kidney disease-related events. The randomized,
Ozempic Link to Rare Vision Loss Risk Confirmed in Study
Novo Nordisk A/S’s blockbuster shot Ozempic was linked to an increased risk of a rare form of vision loss in a study that ...
Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
Is Ozempic safe for weight loss? What doctors want you to know
Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...
24/7 Wall St1d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Ozempic could be linked to a common cause of sudden blindness, study finds
Novo Nordisk’s (NVO) blockbuster diabetes drug Ozempic may have a potential link with an eye condition that causes vision ...
Novo Nordisk's Ozempic reportedly linked to vision loss in new study
GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study, which has yet to be peer-reviewed, ...
Business Insider2d
Novo Nordisk’s Ozempic® Gains EMA Positive Opinion for Kidney Disease Risk Reduction
Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion on updating the Ozempic® label to reflect data from the ...
Novo Nordisk to boost production with a new acquisition
Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge
(Bloomberg) -- Novo Nordisk A/S can advance with its acquisition of factories ... of Novo’s push to build capacity for ...